Together, these results suggest that the role of P-gp in pediatric glioma patients is limited to the BBB, and that an anti-tumor effect of therapeutics that are substrate for P-gp is not ruled out when these barriers are bypassed by intratumoral administration. The gene discussed is PGP; the disease is glioma.